Abstract 249: Economic Outcomes for Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention and Receiving Prasugrel or Ticagrelor: A Retrospective US Hospital Database Analysis [Session Title: Poster Session II]

Conclusion: Economic outcomes of ACS-PCI pts receiving pras were similar to ticag for the primary population with significant savings in total and medical costs for pts without prior TIA or stroke. These data indicate that ticag has no economic advantage compared with pras in routine clinical practice.

Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Molife, C., Frech-Tamas, F., Effron, M. B., DeKoven, M., Karkare, S., Zhu, Y. E., Larmore, C., Lu, J., Lee, W. C., Mc Collam, P., Marrett, E., Vetrovec, G. W. Tags: Session Title: Poster Session II Source Type: research